US EditionDrugmakers Raised Prices on Hundreds of Drugs Despite Trump Deals, Report Finds
The report says 2025 profits reached $177 billion as drugmakers kept raising list prices and launching new medicines at six- and seven-digit prices.
- On Thursday, a Senate report released by Sen. Bernie Sanders, I-Vt., found that drug companies partnering with President Donald Trump raised costs for hundreds of medications, contradicting his claims that deals would lower U.S. prices.
- Trump's "Most Favored Nation" policy aimed to compel manufacturers to charge Americans prices matching cheaper foreign markets, but Senate findings suggest these deals have had little meaningful impact on patient costs.
- Data shows pharmaceutical firms increased costs for drugs including Bristol Myers Squibb's Opdivo to $260,000 and Novartis's Zolgensma to more than $2.5 million, while combined profits surged to $177 billion in 2025.
- White House spokesperson Kush Desai dismissed the findings as "meaningless," while Vanderbilt University professor Stacie Dusetzina criticized the lack of transparency, noting efforts mostly serve to benefit drug manufacturers.
- Health Secretary Robert F. Kennedy Jr. faces upcoming congressional testimony on the budget, where he will likely address concerns regarding drug affordability following last year's Medicaid cuts under the "Big Beautiful Bill" tax package.
12 Articles
12 Articles
Big Pharma gouging consumers as Trump's touted drug deals fall flat: Senate report
President Donald Trump unveiled a health care plan called the "Most Favored Nation" policy, to try to compel drug manufacturers to charge Americans no more for drugs than their cost in the foreign country where they are sold most cheaply — but a new Senate report reveals drug companies are continuin...
NBC Bay Area
Drugmakers raised prices on hundreds of drugs despite Trump deals, report finds
President Donald Trump has repeatedly said his deals with drugmakers would bring down prescription drug prices in the U.S. But a report released by Senate Democrats finds prices have continued to climb — in some cases, sharply. The report — released Thursday by Sen. Bernie Sanders, I-Vt., the ranking member on the Senate Health, Education, Labor and Pensions Committee, ahead of a hearing focused on drug prices — found that companies that signed …
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
